Otto Metzger, MD
Medical Oncology · Boston, MANPI 1275875155
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Merck at 48.1% of the total. 2025 is the largest year on record at $24,197, 4.1 times the $5,887 reported in 2019.
Across 34 payments — averaging $2118.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$35K
- Pfizer$23K
- Sanofi$5K
- AbbVie$4K
- Astrazeneca UK Limited$4K
- Jazz Pharmaceuticals Inc.$2K
- plus $327 from 3 others
Across 183 payments — averaging $774,869 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$141.8M
- F. Hoffmann-la Roche AG$842
What the payments were for
- Consulting fees$31,96144%
- Speaking & faculty fees$28,92940%
- Travel & lodging$10,37914%
- Food & beverage$7031%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 10 | $34,627 |
| Pfizer | 12 | $22,557 |
| Sanofi | 1 | $5,190 |
| AbbVie | 3 | $3,903 |
| Astrazeneca UK Limited | 3 | $3,763 |
| Jazz Pharmaceuticals Inc. | 1 | $1,648 |
| Covis Pharma GmbH | 1 | $200 |
| Roche Products Limited | 2 | $84 |
| AstraZeneca | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$72,015 in reported general payments places this provider in the 80th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 36 | $893 |
| Tamoxifen Citrate | 19 | $275 |
| Prochlorperazine Maleate | 13 | $114 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Boston
- George DemetriBoston$1.6M
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Jeremy AbramsonBoston$334K
- Justin GainorBoston$324K
- Narjust FlorezBoston$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.